![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
Otsuka pens $670M pact to point Harbour's preclinical T-cell engager toward autoimmune disease
Aiming T-cell engagers at autoimmune diseases continues to be a red-hot dealmaking target, as evidenced by Otsuka Pharmaceutical’s decision to pay $47 million upfront for the ex-China rights to Harbour BioMed’s BCMAxCD3 bispecific candidate.
Aiming T-cell engagers at autoimmune diseases continues to be a red-hot dealmaking target, as evidenced by Otsuka Pharmaceutical’s decision to pay $47 million upfront for the ex-China rights to Harbour BioMed’s BCMAxCD3 bispecific candidate.
